WO2009046147A1 - Imageable rodent model of asthma - Google Patents
Imageable rodent model of asthma Download PDFInfo
- Publication number
- WO2009046147A1 WO2009046147A1 PCT/US2008/078506 US2008078506W WO2009046147A1 WO 2009046147 A1 WO2009046147 A1 WO 2009046147A1 US 2008078506 W US2008078506 W US 2008078506W WO 2009046147 A1 WO2009046147 A1 WO 2009046147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- model
- allergen
- asthma
- lymphocytes
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 65
- 238000011808 rodent model Methods 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 106
- 239000013566 allergen Substances 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000004044 response Effects 0.000 claims abstract description 20
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 19
- 241000283984 Rodentia Species 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 210000004072 lung Anatomy 0.000 claims description 82
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 47
- 241001465754 Metazoa Species 0.000 claims description 17
- 210000004241 Th2 cell Anatomy 0.000 claims description 14
- 102000034287 fluorescent proteins Human genes 0.000 claims description 13
- 108091006047 fluorescent proteins Proteins 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- 240000007817 Olea europaea Species 0.000 claims description 6
- 230000001088 anti-asthma Effects 0.000 claims description 6
- 239000000924 antiasthmatic agent Substances 0.000 claims description 6
- 239000000428 dust Substances 0.000 claims description 6
- 229940046528 grass pollen Drugs 0.000 claims description 6
- 238000007912 intraperitoneal administration Methods 0.000 claims description 6
- 238000012634 optical imaging Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 3
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 3
- 241001674044 Blattodea Species 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 241000209082 Lolium Species 0.000 claims description 3
- 241000746983 Phleum pratense Species 0.000 claims description 3
- 210000000969 egg white Anatomy 0.000 claims description 3
- 235000014103 egg white Nutrition 0.000 claims description 3
- 229940062713 mite extract Drugs 0.000 claims description 3
- 229940064402 aspergillus fumigatus extract Drugs 0.000 claims description 2
- 241000222290 Cladosporium Species 0.000 claims 2
- 241000238710 Dermatophagoides Species 0.000 claims 2
- 241000223602 Alternaria alternata Species 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000032258 transport Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 108010058846 Ovalbumin Proteins 0.000 description 67
- 229940092253 ovalbumin Drugs 0.000 description 65
- 239000005090 green fluorescent protein Substances 0.000 description 64
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 60
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 60
- 241000699670 Mus sp. Species 0.000 description 39
- 210000003979 eosinophil Anatomy 0.000 description 30
- 108010054624 red fluorescent protein Proteins 0.000 description 26
- 238000009825 accumulation Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 16
- 230000008595 infiltration Effects 0.000 description 16
- 238000001764 infiltration Methods 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 15
- 230000036428 airway hyperreactivity Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000011740 C57BL/6 mouse Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000005284 excitation Effects 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 238000012800 visualization Methods 0.000 description 8
- 201000009961 allergic asthma Diseases 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 5
- 238000012632 fluorescent imaging Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229960002329 methacholine Drugs 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 229960004784 allergens Drugs 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000003040 circulating cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000242743 Renilla reniformis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 208000037884 allergic airway inflammation Diseases 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035874 hyperreactivity Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 238000013296 A/J mouse Methods 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 101100068321 Aequorea victoria GFP gene Proteins 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102100029137 L-xylulose reductase Human genes 0.000 description 1
- 108010080643 L-xylulose reductase Proteins 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011846 endoscopic investigation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- -1 lungs Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108010012459 ovalbumin-alum Proteins 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Definitions
- the invention relates to a rodent model for asthma. More particularly, it concerns a rodent model for asthma which has fluorescently labeled cells whose trafficking can be monitored after the inducement of an asthmatic response. Methods to determine the effectiveness of candidate drugs that regulate asthmatic responses using the rodent asthma model are also provided.
- Asthma is an immunological disease characterized by the Th2-driven inflammation in the airways. Inflammation in the peribronchial space, with increased production of airway mucus, and airway hyperreactivity (AHR), are cardinal features of asthma.
- Ovalbumin (OVA) challenge models of asthma offer many opportunities for increasing our understanding of the pathogenetic mechanisms underlying this disease, as well as for identifying novel therapeutic targets.
- OVA Ovalbumin
- Antigen-induced mouse models of pulmonary allergic disease have proved particularly informative in the genetic dissection of inflammatory pathways in the lung.
- Kung et al. developed a method for inducing severe pulmonary eosinophilia in the mouse and also studied the numbers of eosinophils in blood and bone marrow and the response to corticosteroid treatment. (Kung et al., Int Arch Allergy Immunol. 1994; 105:83-90.) Animals were sensitized with alum-precipitated OVA and challenged with aerosolized OVA 12 days later when serum IgE levels were significantly elevated.
- BAL bronchoalveolar lavage
- Pauwels et al. developed a murine in vivo model of allergic airway inflammation characterized by the presence of IgE antibodies to an inhaled antigen, peribronchial infiltrates with an increased number of eosinophils, and increased airway responsiveness to nonantigenic bronchoconstrictor stimuli.
- the C57 Black 6 (C57B1/6) mice were actively sensitized on Day 0 by intraperitoneal injection of 10 ⁇ g of OVA adsorbed to 1 mg of alum and from Day 14 to 21 exposed daily to aerosolized OVA over a 30-min period.
- U.S. patent application 11/568,896 (Publication No. US 2008-0172751) describes a mouse model of COPD and ThI asthma induced by OVA and double stranded RNA (dsRNA).
- BALB/c mice (Jackson Lab, USA) were sensitized by administrating synthesized dsRNA ployinosinic-polycytidylic acid (PoIyIC, Sigma, USA) and OVA intranasally, singly or together, four times. Ten days later, the mice were challenged with the intranasal administration of OVA to induce asthma. The resultant mice were named ThI asthma mice. The negative control mice were administered only with phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- U.S. Patent No. 6,215,040 describes a transgenic mouse that constitutively expressed IL-5 in lung epithelium resulting in a dramatic accumulation of peribronchial eosinophils and striking pathological changes including expansion of bronchus-associated lymphoid tissue (BALT), goblet cell hyperplasia, epithelial hypertrophy and focal collagen deposits. Surprisingly, these changes were not accompanied by a prominent eosinophil infiltration into the airway lumen. Thus, lung-specific expression of IL-5 alone (i.e., in the absence of antigen- induced pulmonary inflammation) can induce many of the pathologic changes associated with allergic respiratory disease. Moreover, these mice displayed AHR in response to methacholine challenge. Thus, AHR can occur without extensive infiltration of the airway lumen by eosinophils.
- BALT bronchus-associated lymphoid tissue
- goblet cell hyperplasia goblet cell hyperplasia
- mice had similar early and late asthmatic responses peaking at 2 h and 7-8 h, respectively.
- IgE and IgG antibody levels compared with na ⁇ ve mice, and eosinophil infiltration, compared with na ⁇ ve and saline challenge, were elevated. Airway hyperresponsiveness to methacholine was observed 24 h after challenge in both models.
- the acute model had higher levels of eosinophilia, whereas the chronic model showed hyperresponsiveness to lower doses of methacholine and had higher levels of total IgE and ovalbumin-specific IgG antibodies.
- Both novel murine models of allergic asthma bear a close resemblance to human asthma, each offering particular advantages for studying the mechanisms underlying asthma and for evaluating existing and novel therapeutic agents.
- CD4 + type-2 helper T Th2 cells
- CD4 + Th2 cells which are thought to be present in the airways of all patients with asthma, secrete key cytokines, such as IL-4 and IL-13, as well as IL-5 and IL-9.
- Conventional CD4 + T cells recognize exogenous antigens and initiate allergic inflammation in the lungs and, in mouse models of asthma, elimination of CD4 + cells abrogates the development of AHR.
- Th2 cytokines interleukin (IL)-5 and IL-13 in particular.
- IL interleukin
- Th2-driven immune responses are vitally important in the development of asthma, in itself a Th2 response is not sufficient to induce asthma.
- a better understanding of the role of regulatory cells in asthma may lead to the identification of novel therapeutic targets.
- pulmonary eosinophilia has been recognized as a predominant feature of the inflammatory infiltrate, which often correlates with disease severity.
- Recently, there has been increasing interest in the involvement of eosinophils in the pathogenesis of asthma. Weller, P.F., Curr. Opin. Immunol. 1994; 6:85-90.
- a spectrum of CD4 + T cells including Th3 cells, T R cells, CD4 + CD25 + cells and NKT cells play a critical role in regulating this disease.
- Fluorescent proteins have been used as fluorescent labels for a number of years. The originally isolated protein emitted green wavelengths and came to be called green fluorescent protein (GFP). Because of this, green fluorescent protein became a generic label for such fluorescent proteins in general, although proteins of various colors including red fluorescent protein (RFP), blue fluorescent protein (BFP) and yellow fluorescent protein (YFP) among others have been prepared. The nature of these proteins is discussed in, for example, U.S. Patent Nos. 6,232,523; 6,235,967; 6,235,968; and 6,251,384. These patents describe the use of fluorescent proteins of various colors to monitor tumor growth and metastasis in transgenic rodents which are convenient tumor models.
- RFP red fluorescent protein
- BFP blue fluorescent protein
- YFP yellow fluorescent protein
- a dual-color fluorescence imaging model of tumor-host interaction based on an RFP-expressing tumor growing in GFP transgenic mice, enabling dual-color visualization of the tumor-stroma interaction including tumor angiogenesis and infiltration of lymphocytes in the tumor has been described.
- Transgenic mice expressing the GFP under the control of a chicken beta-actin promoter and cytomegalovirus enhancer were used as the host (Okabe et al, FEBS Lett 1997; 407:315-319). All of the tissues from this transgenic line fluoresce green under blue excitation light.
- B16F0 B16F0-RFP
- the B 16F0-RFP tumor and GFP-expressing host cells could be clearly imaged simultaneously.
- High-resolution dual-color images enabled resolution of the tumor cells and the host tissues down to the single cell level.
- Host cells including fibroblasts, tumor infiltrating lymphocytes, dendritic cells, blood vessels and capillaries that express GFP, could be readily distinguished from the RFP-expressing tumor cells.
- This dual-color fluorescence imaging system should facilitate studies for understanding tumor-host interaction during tumor growth and tumor angiogenesis.
- the dual-colored chimeric system also provides a powerful tool to analyze and isolate tumor infiltrating lymphocytes and other host stromal cells interacting with the tumor for therapeutic and diagnostic/analytic purposes.
- the above reference is incorporated herein by reference.
- Yang et al. conducted whole-body optical imaging of GFP-expressing tumors and metastases (Yang et al. , Proc. Natl. Acad. ScL (U S A) 2000; 97: 1206-11). Yang et al. have imaged, in real time, fluorescent tumors growing and metastasizing in live mice. The whole -body optical imaging system is external and noninvasive. It affords unprecedented continuous visual monitoring of malignant growth and spread within intact animals. Yang et al. have established new human and rodent tumors that stably express very high levels of the Aequorea victoria GFP and transplanted these to appropriate animals.
- B16F0-GFP mouse melanoma cells were injected into the tail vein or portal vein of 6-week-old C57BL/6 and nude mice.
- Whole -body optical images showed metastatic lesions in the brain, liver, and bone of B16F0-GFP that were used for real time, quantitative measurement of tumor growth in each of these organs.
- the AC3488-GFP human colon cancer was surgically implanted orthotopically into nude mice.
- Whole-body optical images showed, in real time, growth of the primary colon tumor and its metastatic lesions in the liver and skeleton. Imaging was with either a trans - illuminated epifluorescence microscope or a fluorescence light box and thermoelectrically cooled color charge-coupled device camera.
- the depth to which metastasis and micrometastasis could be imaged depended on their size. A 60-micrometer diameter tumor was detectable at a depth of 0.5 mm whereas a 1, 800-micrometer tumor could be visualized at 2.2-mm depth.
- the simple, noninvasive, and highly selective imaging of growing tumors made possible by strong GFP fluorescence, enables the detailed imaging of tumor growth and metastasis formation. This should facilitate studies of modulators of cancer growth including inhibition by potential chemotherapeutic agents.
- the whole-body external fluorescent optical imaging technology shown above is disclosed in U.S. Patent No. 6,649,159.
- the present invention is directed to a rodent model for asthma with fluorescently labeled cells whose trafficking can be monitored after an asthmatic response has been induced.
- the model is a rodent that has been provided allergen-sensitized, fluorescently labeled lymphocytes which can be detected after inducing an asthmatic response to said allergen.
- the invention is directed to a method to monitor cell trafficking in the rodent asthma model.
- the invention is directed to methods to screen for anti- asthma drugs using the rodent model by looking for drugs that specifically inhibit the trafficking of the fluorescent cells responsible for the asthmatic response.
- Figure 1 Dual color visualization of GFP + CD4 + T cell infiltration into the lung in OVA-induced allergic asthma.
- Figure 2. Dual color visualization of RFP + CD4 + T cell infiltration into the lung in OVA-induced allergic asthma.
- FIG. 1 Figure 3. Visualization of CD8 + T cell infiltration into the lung in OVA-induced allergic asthma.
- Figure 4 Time course and Dexamethasone inhibition of CD4 + T cell accumulation in the lung.
- Figure 5 Time course and Dexamethasone inhibition of CD4 + T cell accumulation in the lung by fluorescent imaging.
- Figure 7 Histological and immunohistochemical analysis for the induction of inflammatory foci and GFP + Th2 cell foci after allergen challenge.
- fluorescent protein In order to avoid confusion, the simple term "fluorescent protein” will be used; in general, this is understood to refer to the fluorescent proteins which are produced by various organisms, such as Renilla and Aequorea as well as modified forms of these native fluorescent proteins which may fluoresce in various visible colors, such as red, yellow, and cobalt, which are exhibited by red fluorescent protein (RFP), yellow fluorescent protein (YFP) or cobalt fluorescent protein (CFP), respectively.
- RFP red fluorescent protein
- YFP yellow fluorescent protein
- CFP cobalt fluorescent protein
- the invention provides a rodent model for asthma wherein the rodent has been provided allergen-sensitized, fluorescently labeled lymphocytes which can be detected after inducing an asthmatic response to said allergen.
- the fluorescently labeled lymphocytes can be T lymphocytes. In another specific embodiment, the fluorescently labeled lymphocytes can be CD4 + T lymphocytes. In yet another specific embodiment, the fluorescently labeled lymphocytes can be Th2 cells.
- the rodent may be, for instance, a mouse or rat.
- Mouse strains suitable may be BALB/c, C57BL/6, B6D2F1/J, A/J, CBA/J, etc.
- Allergens for challenge and sensitization may be OVA, OVA peptide, sheep red blood cells, dsRNA, cockroach (rBla g2), house dust mite (rDer f 1), house dust mite-extract, olive pollen (natural and recombinant Ole el), Aspergillus fumigatus-extract, Timothy grass pollen (rPhl p5), birch pollen (rBet vl), rye grass pollen (LoI pi), olive pollen extract, Alternaria alternate-extract, Cl ⁇ dosporium herb ⁇ rum-spores, Derm ⁇ toph ⁇ goides pteronys sinus -extract, heat-coagulated hen's egg white, etc., or any combination thereof.
- the route of challenge may be inhalation, or intratracheal, intranasal, intraperitoneal, or subcutaneous injection, etc.
- the fluorescently labeled cells come from a donor mouse which expresses a fluorescent protein ubiquitously or in a subset of cells.
- the donor mouse may be sensitized prior to the collection of the fluorescently labeled cells to be introduced to the recipient mouse.
- Sensitization may be performed with either of the above listed allergens, or any combination thereof, with or without an adjuvant(s).
- Adjuvants used may be alum, HDM/CFA, 1 IFA, 2 PT, 3 etc., or any combination thereof.
- the route of sensitization may be intraperitoneal, intranasal, intratracheal, or subcutaneous injection, etc.
- the fluorescently labeled cells come from two donor animal which express two different fluorescent proteins. One donor is sensitized while the other donor is not sensitized and is used as control. The two distinctively labeled cell populations are introduced to the same recipient animal and their trafficking may be monitored simultaneously by dual-color fluorescence imaging described above.
- This invention further provides a method to determine the effectiveness of candidate anti-asthma drugs by administering the substance to the rodent model for asthma followed by monitoring the inhibitory effects on cell trafficking.
- Administration of the candidate substance can be performed before, after, or simultaneously with the challenge on the animal to induce asthmatic responses.
- Dual-color fluorescent imaging may be used to monitor the effects of the candidate substance on sensitized and control cell populations in order to filter out false positives.
- Cell trafficking may be monitored in tissue sections that have been excised, in living tissues ex vivo, or in living animals in vivo.
- tissue sections that have been excised, in living tissues ex vivo, or in living animals in vivo.
- endoscopy or whole-body fluorescent imaging may be performed, which is described in more detail in the sections that follow.
- the label used in the various aspects of the invention is a fluorescent protein.
- the native gene encoding the seminal protein in this class, GFP, has been cloned from the
- PT pertussis toxin bioluminescent jellyfish Aequorea victoria (Morin et al, J. Cell Physiol. 1972; 77:313-318).
- GFP pertussis toxin bioluminescent jellyfish Aequorea victoria
- GFP-S65T wherein serine at 65 is replaced with threonine is particularly useful in the present invention method and has a single excitation peak at 490 nm.
- GFP green fluorescent proteins falling within the definition of "GFP" herein have been isolated from other organisms, such as the sea pansy, Renilla reniformis. Any suitable and convenient form of GFP can be used to modify the infectious agents useful in the invention, both native and mutated forms.
- the methods of the invention utilize fluorescently labeled cells, preferably of sufficient fluorescence intensity that the fluorescence can be seen in the subject without the necessity of any invasive technique. While whole body imaging is preferred because of the possibility of real-time observation, endoscopic techniques, for example, can also be employed or, if desired, tissues or organs excised for direct or histochemical observation.
- endoscopy can be used as well as excision of individual tissues, it is particularly convenient to visualize the migration of cells in the intact animal through fluorescent imaging.
- This permits real-time observation and monitoring of cell trafficking on a continuous basis, in particular, in model systems, in evaluation of potential anti-asthma drugs and protocols.
- the inhibition of cell trafficking observed directly in test animals administered a candidate drug or protocol in comparison to controls which have not been administered the drug or protocol indicates the efficacy of the candidate and its potential as a treatment.
- the availability of fluorescent imaging permits those devising treatment protocols to be informed on a continuous basis of the advisability of modifying or not modifying the protocol.
- Fluorescence imaging See Yang, M., Proc. Natl. Acad. Sci. USA 2002; 99:3824-3829.
- a Leica fluorescence stereo microscope model LZ12 equipped with a mercury 50W lamp power supply is used for initial lower resolution imaging.
- excitation is produced through a D425/60 band pass filter and 470 DCXR dichroic mirror.
- Emitted fluorescence is collected through a long pass filter GG475 (Chroma Technology, Brattleboro, VT). Macroimaging is carried out in a light box (Lightools Research, Encinitas, CA).
- Fluorescence excitation of both GFP and RFP tumors is produced in the lightbox through an interference filter (440+/-20 nm) using slit fiber optics. Fluorescence is observed through a 520 nm long pass filter. Images from the microscope and light box are captured on a Hamamatsu C5810 3-chip cool color CCR camera (Hamamatsu Photonics Systems, Bridgewater, NJ). Laser-based imaging is carried out with the Spectra Physics model 3941-M1BB dual photon laser, Photon Technology Intl. model GL-3300 nitrogen laser and the Photon Technology Intl. model GL-302 dye laser. Images are processed for contrast and brightness and analyzed with the use of Image Pro Plus 4.0 software (Media Cybernetics, Silver Springs, Maryland). High resolution images of 1024x724 pixels are captured directly on an IBM PC or continuously through video output on a high resolution Sony VCR model SLV- RlOOO (Sony Corp., Tokyo Japan).
- Multiphoton confocal microscopy Wang et al. , Cancer Res. 2002; 62:6278-6288.
- the dual photon laser Spectra-Physics model 3941-M1BB
- the Radiance 2000 multiphoton system Bio-Rad, Hercules, CA
- the images are collected using Bio-Rad' s Lasersharp 2000 software. Excitation is confined only to the optical section being observed. No excitation of the fluorophore will occur at 960 nm wavelength not in the plane of focus.
- Spectral resolution is the generation of images containing a high-resolution optical spectrum at every pixel, to "unmix" the RFP signal from that of the GFP-labeled cells.
- the standard GFP-mouse imaging system long-pass emission filter
- the standard GFP-mouse imaging system is modified by replacing the usual color camera with the cooled monochrome camera (Roper Scientific CCD thermo-cooled digital camera) and a liquid crystal tunable filter (CRI, Inc., Woburn, MA) positioned in front of a conventional macro-lens.
- a series of images is taken every 10 nm from 500 to 650 nm and assembled automatically in memory into a spectral "stack.”
- the image can be resolved into different images using a linear combination chemometrics-based algorithm that generates images containing only the autofluorescence signals or only the GFP or RFP signals, now visible against essentially a black background.
- spectral autofluorescence subtraction sensitivity is enhanced due to improvements in signal to noise ratio.
- GFP- or RFP-labeled cells which allow noninvasive, and highly selective imaging, are further enhanced by using wavelength-selective imaging techniques and analysis to image cell trafficking on deep organs such as the lung (personal communication, Richard Levenson, CRI, Inc., Woburn, MA).
- mice C57BL/6 were purchased from Charles River Laboratories. C57BL/6- Tg(CAG-EGFP)C14-Y01-FM131Osb (GFP Tg, C57BL/6 background) mice expressing an enhanced GFP in the whole body (Okabe et al, FEBS Lett. 1997; 407:313-319) were provided by Dr. Okabe (Osaka University, Japan). OVA-specific TCR ⁇ transgenic (OT2 Tg) mice were maintained under specific-pathogen-free conditions. All animal care was carried out in accordance with guidelines of Chiba University and Anticancer, Inc.
- GFP or RFP Tg mice were immunized intraperitoneally with 250 ⁇ g OVA (chicken egg albumin from Sigma) in 4mg aluminum hydroxide gel (alum) on day 0 and 7.
- Splenic CD4 + T cells from OVA-sensitized GFP or RFP Tg mice were isolated by magnetic negative selection using a CD4 + T cell isolation kit (Miltenyi Biotec) on day 14, yielding a purity of >98%.
- These cells (2 x 10 7 cells) or OVA- specific Th2 cells (5 x 10 6 cells) were transferred intravenously through the tail vain to 8-wk-old C57BL/6 recipient mice.
- the recipient mice inhaled aerosolized OVA in saline (10 mg/ml) for 30 min using a supersonic nebulizer (NE-U07, Omron Co. Japan).
- Lung histology and immunohistochemistry Mice were sacrificed by CO 2 asphyxiation at indicated time after the OVA inhalation, and the lungs were infused with 10% (v/v) formalin in PBS or 4% (v/v) paraformaldehyde for fixation. The lung samples were sectioned, stained with H&E reagents, and examined for pathological changes under a light microscope at x50 or x200. Lung specimens were embedded in Tissue-Tek OCT compound, frozen in liquid nitrogen, and cut by a cryostat into 6- ⁇ m-thick sections.
- GFP Tg mice were sensitized with OVA-alum on days 0 and 7.
- Splenic CD4 + T cells from OVA- sensitized GFP Tg and non- sensitized RFP Tg mice were purified and injected into normal C57BL/6 mice on day 14. The recipient mice were exposed to aerosolized OVA allergen challenge by airway administration on day 15. On day 16, GFP + and RFP + CD4 + T cells on the surface of the lung were monitored by OVlOO microscopy (Fig. Ia).
- Splenic CD4 + T cells from OVA-sensitized GFP Tg mice were injected into recipient C57BL/6 mice, and the recipient mice were exposed to an allergen challenge as described in Example 1.
- GFP + CD4 + T cells on the surface of the lung were monitored at 24 hours (Fig. 4a and 5a) and 72 hours (Fig. 4b and 5b) after OVA inhalation by OVlOO microscopy.
- Migration of GFP + CD4 + T cells into the lung was first detected at 12 hours after OVA inhalation, and the maximum number of CD4 + T cells was detected at 18 to 36 hours after OVA inhalation. While eosinophil infiltration is characteristic in allergic airway inflammation, these results indicate that CD4 + T cell accumulation in the lung after the allergen challenge occurs prior to infiltration of eosinophils, and sustains to at least 72 hours after the allergen challenge.
- This imageable model proves useful to monitor the migration of inflammatory lymphocytes in the asthmatic lung.
- Dexamethasone a potent drug which attenuates allergic reactions, was administered to the recipient mice before the allergen challenge.
- OVA-specific Th2 cells were induced in vitro from naive CD4 + T cells from GFP Tg x OT2 Tg mice.
- the number and size of the foci increased 12 hours after OVA inhalation. GFP + cell number in non- focus area also increased but not significantly until 12 hours after OVA inhalation. The number of foci further increased 18 h after OVA inhalation, and GFP + cell number in non-focus area increased significantly between 12 and 18 hours after OVA inhalation. Eighteen hours after OVA inhalation or later, the border of foci became unclear and foci began to merge.
- Circulating OT2-Th2 cells into the lung significantly decreased compared with that of 12 h after OVA inhalation, from 44.7 ⁇ 4.5 to 2.7 ⁇ 0.6 cells/mm 2 /30min (Table 1).
- OT2-Th2 cell accumulation in the lung and exiting from the lung also significantly decreased 21 h after OVA inhalation. More than 95% of accumulating cells were motive.
- OT2-Th2 cells accumulated in the whole area of the lung in addition to the focus areas.
- GFP + OT2-Th2 cells were intravenously transferred into C57BL/6 mice. Two days later, recipient mice were exposed to an allergen challenge by OVA inhalation. Infiltration and focus formation of eosinophils were observed by H&E staining (Fig. 7a). Infiltrated OT2-Th2 cells were detected by immunohistochemistry with an anti-GFP antibody (Fig. 7b). Twenty- four hours after OVA inhalation, GFP + OT2-Th2 cells infiltrated into the lung and formed foci, but eosinophils did not infiltrate (Fig. 7).
- OT2-Th2 cells infiltrate into the lung in advance of eosinophils after allergen exposure, and might regulate the formation of inflammatory foci.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010527255A JP2010539951A (en) | 2007-10-01 | 2008-10-01 | An imageable rodent asthma model |
US12/681,348 US20110033388A1 (en) | 2007-10-01 | 2008-10-01 | Imageable rodent model of asthma |
CN2008801187427A CN101883587A (en) | 2007-10-01 | 2008-10-01 | Imageable rodent model of asthma |
AU2008308697A AU2008308697A1 (en) | 2007-10-01 | 2008-10-01 | Imageable rodent model of asthma |
EP08836207A EP2187963A4 (en) | 2007-10-01 | 2008-10-01 | Imageable rodent model of asthma |
CA2700543A CA2700543A1 (en) | 2007-10-01 | 2008-10-01 | Imageable rodent model of asthma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97674907P | 2007-10-01 | 2007-10-01 | |
US60/976,749 | 2007-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009046147A1 true WO2009046147A1 (en) | 2009-04-09 |
Family
ID=40526655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/078506 WO2009046147A1 (en) | 2007-10-01 | 2008-10-01 | Imageable rodent model of asthma |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110033388A1 (en) |
EP (1) | EP2187963A4 (en) |
JP (1) | JP2010539951A (en) |
KR (1) | KR20100089839A (en) |
CN (1) | CN101883587A (en) |
AU (1) | AU2008308697A1 (en) |
CA (1) | CA2700543A1 (en) |
WO (1) | WO2009046147A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3621988A1 (en) | 2017-05-09 | 2020-03-18 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
WO2019113509A2 (en) | 2017-12-08 | 2019-06-13 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining car-t cell efficacy |
EP3728189A1 (en) | 2017-12-20 | 2020-10-28 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
CN108445227B (en) * | 2018-03-13 | 2020-05-15 | 中国农业大学 | Method for detecting allergen in food in vitro |
KR102275276B1 (en) * | 2019-02-27 | 2021-07-09 | 연세대학교 산학협력단 | Animal model of allergic respiratory disease and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050019260A1 (en) * | 2001-06-04 | 2005-01-27 | Meeusen Elza Nicole Theresia | Animal model for allergy |
US20060130161A1 (en) * | 2004-10-12 | 2006-06-15 | Carantech, Inc. | Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025539A (en) * | 1996-04-09 | 2000-02-15 | Mayo Foundation For Medical Education And Research | IL-5 transgenic mouse |
CN1264429A (en) * | 1997-04-28 | 2000-08-23 | 抗癌股份有限公司 | Metastasis models using green fluorescent protein (GFP) as marker |
US6232523B1 (en) * | 1997-04-28 | 2001-05-15 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
US6251384B1 (en) * | 1997-04-28 | 2001-06-26 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
AU2001249297B2 (en) * | 2000-03-17 | 2006-11-23 | Anticancer, Inc. | Whole-body optical imaging of gene expression and uses thereof |
AU2003275990A1 (en) * | 2002-09-26 | 2004-04-19 | Novartis Ag | Tcell mediator/modulator assay based upon tcell restricted transgenic mouse |
KR100785969B1 (en) * | 2004-05-12 | 2007-12-14 | 동아제약주식회사 | An agent comprising fgf2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease |
-
2008
- 2008-10-01 WO PCT/US2008/078506 patent/WO2009046147A1/en active Application Filing
- 2008-10-01 CN CN2008801187427A patent/CN101883587A/en active Pending
- 2008-10-01 JP JP2010527255A patent/JP2010539951A/en active Pending
- 2008-10-01 KR KR1020107009736A patent/KR20100089839A/en not_active Application Discontinuation
- 2008-10-01 US US12/681,348 patent/US20110033388A1/en not_active Abandoned
- 2008-10-01 EP EP08836207A patent/EP2187963A4/en not_active Withdrawn
- 2008-10-01 CA CA2700543A patent/CA2700543A1/en not_active Abandoned
- 2008-10-01 AU AU2008308697A patent/AU2008308697A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050019260A1 (en) * | 2001-06-04 | 2005-01-27 | Meeusen Elza Nicole Theresia | Animal model for allergy |
US20060130161A1 (en) * | 2004-10-12 | 2006-06-15 | Carantech, Inc. | Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes |
Non-Patent Citations (3)
Title |
---|
DOZMOROV ET AL.: "Generation of Antigen-Specific Th2 Cells from Unprimed Mice In Vitro: Effects of Dexamethasone and Anti-IL-10 Antibody1.", J. OF IMMUNOLOGY, vol. 160, 1998, pages 2700 - 2705 * |
SCHUSTER ET AL.: "Lymphocytes Migrate from the Blood into the Bronchoalveolar Lavage and Lung Parenchyma in the Asthma Model of the Brown Norway", RAT. AM. J. RESPIR. CRIT. CARE MED., vol. 161, no. 2, February 2000 (2000-02-01), pages 558 - 566 * |
See also references of EP2187963A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2008308697A1 (en) | 2009-04-09 |
KR20100089839A (en) | 2010-08-12 |
JP2010539951A (en) | 2010-12-24 |
EP2187963A1 (en) | 2010-05-26 |
CA2700543A1 (en) | 2009-04-09 |
US20110033388A1 (en) | 2011-02-10 |
CN101883587A (en) | 2010-11-10 |
EP2187963A4 (en) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meira et al. | A hippocampal circuit linking dorsal CA2 to ventral CA1 critical for social memory dynamics | |
US20190046554A1 (en) | Control and characterization of memory function | |
EP2635346B1 (en) | Optogenetic control of reward-related behaviors | |
US20110033388A1 (en) | Imageable rodent model of asthma | |
Del Castillo et al. | Genetics of isolated auditory neuropathies | |
US20080038204A1 (en) | Whole Body Imaging Using Portable Observation Systems | |
Priest et al. | Peptidergic modulation of fear responses by the Edinger-Westphal nucleus | |
Portal et al. | Preclinical mouse model to monitor live Muc5b-producing conjunctival goblet cell density under pharmacological treatments | |
MXPA02004954A (en) | Transgenic mice expressing fluorescent protein under the control of the nestin promoter. | |
US8952213B2 (en) | Neuronal activation in a transgenic model | |
Hoffman | Nestin-driven green fluorescent protein as an imaging marker for nascent blood vessels in mouse models of cancer | |
Lee et al. | Brn3b regulates the formation of fear-related midbrain circuits and defensive responses to visual threat | |
KR101142610B1 (en) | Immunocompromised rodents as dual color tumor models | |
WO2013102118A2 (en) | Imageable patient tumors in mice | |
Dong et al. | Patch and matrix striatonigral neurons differentially regulate locomotion | |
Cai et al. | Patch and matrix striatonigral neurons differentially regulate locomotion | |
Ash | Investigating projections from the ventral hippocampus (vHC) to the prelimbic (PL) and infralimbic (IL) cortices in the mouse | |
US20220048970A1 (en) | Cell Body Targeted Sensors | |
Tsai | Deciphering Principles Governing Retinotectal Synaptic Specificity | |
JP5186637B2 (en) | Transgenic non-human mammal and use thereof | |
JP2021031467A (en) | Method for controlling the activity of opsin | |
Hess | A New Functional Zebrafish Gastrointestinal Motility Assay | |
Greenberg III | Imaging the Cellular Dynamics of Immune-mediated Pathology and Therapeutic Regulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880118742.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08836207 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2700543 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010527255 Country of ref document: JP Ref document number: 2008836207 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008308697 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008308697 Country of ref document: AU Date of ref document: 20081001 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107009736 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12681348 Country of ref document: US |